secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2023-10-05T23:59:59+00:00
Accession:  0001493152-23-035716
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Lixte Biotechnology terminates exclusive MDS license with Moffitt; no termination fee
--------------------------------------------------------------------------------

- Received counter-signed termination letter on Oct 4, 2023, effective Sept 30, 2023.
- No termination fee or further payments owed by Lixte under the license agreement.
- Company had previously disclosed discontinuation of MDS development in June 30, 2023 10-Q.
- License originally granted in August 2018 covering patents for myelodysplastic syndrome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315223035716/0001493152-23-035716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315223035716/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-035716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer